Table 2.
Individual Patient Baseline Characteristics and Response to Treatment with Pembrolizumab
| Case no. | No. of prior systemic therapies | Prior systemic therapies | ECOG performance status | Hormonal status | Metastatic sites at time of studya | PD-L1H-scoreb | TILscorec | MSI status | Maximum % change from baseline |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 4 | Mitotane; ACAT-inhibitor; ipilimumab; cisplatin-gemcitabine | 1 | Cortisol and androgen-producing | 2 | 0 | 2 | NA | 289% increase |
| 2 | 1 | Mitotane | 1 | Non-functioning | 2, 4 | 0 | 2 | Stable | 88% increase |
| 3 | 2 | Mitotane; etoposide-doxorubicin-cisplatin-mitotane | 1 | Androgen-producing | 1, 2, 4, 5 | 0 | 1 | Stable | 56% increase |
| 4 | 1 | Etoposide-doxorubicin-cisplatin-mitotane | 0 | Cortisol and androgen-producing | 2, 4, 5 | 0 | 2 | Stable | 49% increase |
| 5 | 2 | Mitotane; Etoposide-doxorubicin-cisplatin | 1 | Cortisol and androgen-producing | 1, 4, 5 | 0 | 2 | Stable | 43% increase |
| 6 | 1 | Etoposide-carboplatin-mitotane | 1 | Non-functioning | 2, 4 | 0 | 2 | Stable | 15% increase |
| 7 | 5 | Etoposide-doxorubicin-cisplatin-mitotane; ACAT-inhibitor; etoposide-carboplatin-mitotane; mitotane; ipilimumab | 1 | Cortisol and androgen-producing | 1, 2, 4 | 0 | 2 | Stable | 14% increase |
| 8 | 5 | Mitotane; ACAT-inhibitor; etoposide-doxorubicin-cisplatin; ipilimumab; cabozantinib | 1 | Cortisol-producing | 1, 1, 4 | 0 | 1 | Stable | 11% increase |
| 9 | 1 | Mitotane | 0 | Non-functioning | 4 | 0 | 1 | Stable | 6% increase |
| 10 | 1 | Mitotane | 1 | Cortisol and androgen-producing | 1, 2, 3, 5 | 0 | 1 | Stable | 5% increase |
| 11 | 2 | Mitotane; etoposide-doxorubicin-cisplatin | 1 | Non-functioning | 1, 2, 3, 4 | 0 | 3 | Stable | 8% decrease |
| 12 | 2 | Etoposide-doxorubicin-cisplatin-mitotane; mitotane | 1 | Non-functioning | 2 | NA | NA | Stable | 24% decrease |
| 13 | 3 | Mitotane; etoposide-doxorubicin-cisplatin; gemcitabine-docetaxel | 1 | Cortisol and androgen-producing | 1, 6 | NA | NA | Stable | 41% decrease |
| 14 | 4 | Mitotane; etoposide-doxorubicin-cisplatin-mitotane; etoposide-carboplatin; ipilimumab | 0 | Non-functioning | 1, 2 | 0 | 0 | NA | 53% decrease |
| 15 | 1 | Etoposide-doxorubicin-cisplatin-mitotane | 1 | Androgen-producing | 1, 2, 4, 5 | 0 | 1 | Stable | Not restaged |
| 16 | 3 | Etoposide, doxorubicin, carboplatin-mitotane; apatinib; streptozocin | 1 | Androgen-producing | 1, 2, 4 | 0 | 2 | Isolated loss of PMS2 (internal positive control) | Not restaged |
Abbreviations: ACAT-inhibitor Acyl-coenzyme A:cholesterol O-acyltransferase inhibitor, ECOG Eastern Cooperative Oncology Group, MSI Microsatellite instability, NA Not available, PD-L1 Programmed cell death ligand-1, TIL Tumor-infiltrating lymphocyte
aMetastatic sites: 1, liver; 2, lung; 3, bone; 4, adrenal bed; 5, lymph nodes; 6, other
bPD-L1 characterization based on the percentage and intensity of membrane staining
cTILs within tumor nests were scored on a scale from 0 to 3: 0 for absence of TILs, 1 for a few TILs, 2 for a moderate amount of TILs, and 3 for intense intratumoral lymphocytic infiltration